financetom
Business
financetom
/
Business
/
Market Chatter: CVS Store-Brand Medications Face Quality Concerns and Higher Recall Rates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: CVS Store-Brand Medications Face Quality Concerns and Higher Recall Rates
Jun 11, 2024 4:53 AM

07:41 AM EDT, 06/11/2024 (MT Newswires) -- CVS Health ( CVS ) store-brand medications have a higher recall rate than competitors due to quality issues at factories, including contaminated water in production, drugs being too potent and manufacturing oversight, Bloomberg reported on Tuesday.

Over the past decade, CVS's store-brand medications have been recalled about two times more than those from Walgreens Boots Alliance (WBA) and three times more than those from Walmart (WMT), according to a Bloomberg analysis of public records.

Kevin Schulman, a professor of medicine at Stanford University, told Bloomberg that large drug purchasers like pharmacies and hospitals have little incentive to choose suppliers based on quality.

While CVS claims to prioritize manufacturing and sourcing standards, the report said that over the last decade, CVS hired at least 15 manufacturers that were cited for manufacturing problems, more than twice as many as its largest rival, Walgreens.

It added that there were 133 recalls of CVS store-brand drugs -- an average of more than one a month -- in that time frame for both pediatric and adult medications, while Walgreens had 70 recalls over the same period and Walmart had 51.

CVS did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 60.11, Change: -0.17, Percent Change: -0.28

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell
Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell
May 7, 2024
08:58 AM EDT, 05/07/2024 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) reported a Q1 net loss Tuesday of $2.35 per diluted share, wider than the loss of $0.92 a year earlier. Analysts polled by Capital IQ expected a loss of $2.02. Net revenue for the quarter ended March 31 was $26 million, up from $11.5 million a year earlier....
BRIEF-Private Equity Firms Circle Peloton For Potential Buyout  - CNBC
BRIEF-Private Equity Firms Circle Peloton For Potential Buyout - CNBC
May 7, 2024
May 7 (Reuters) - * PRIVATE EQUITY FIRMS CIRCLE PELOTON FOR POTENTIAL BUYOUT - CNBC Source text: https://cnb.cx/3y6Jl7R Further company coverage: ...
Australian Dollar Weakens Following Central Bank's Decision to Keep Cash Rate Unchanged
Australian Dollar Weakens Following Central Bank's Decision to Keep Cash Rate Unchanged
May 7, 2024
08:58 AM EDT, 05/07/2024 (MT Newswires) -- The Australian dollar lost ground during the European trading session on Tuesday after the Reserve Bank of Australia left its cash rate target unchanged at 4.35%, as expected. AUD/USD was at 0.6617 at mid-afternoon in the European session. It earlier fell from 0.6625 to 0.6600 on the decision before easing. The RBA said...
Market Chatter: Apple Reportedly Developing AI Chips for Data Centers
Market Chatter: Apple Reportedly Developing AI Chips for Data Centers
May 7, 2024
08:57 AM EDT, 05/07/2024 (MT Newswires) -- Apple ( AAPL ) is working on its own chip that is designed to run artificial intelligence software in data center servers, The Wall Street Journal reported. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation....
Copyright 2023-2026 - www.financetom.com All Rights Reserved